Effect of Empagliflozin on Endothelial Function in Cardiovascular High Risk Diabetes Mellitus: Multi-Center Placebo-Controlled Double-Blind Randomized Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMBLEM
- 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2017 Status changed from not yet recruiting to recruiting.
- 25 Oct 2016 New trial record